Client News

Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry

ONWARD: convocation of the 2023 annual general meeting of shareholders and proposed resolutions

ONWARD reports 2022 full year financial and operating results

Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 % in institutional database with asunercept plus standard of care in newly diagnosed glioblastoma multiforme patients

Destiny Pharma announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology

Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business

InflaRx reports full year 2022 financial and operating results

A new prestigious scientific publication for Carbios marks the expansion of its research to other plastics

Mainz Biomed to present at Sidoti Virtual Investor Conference March 22-23

Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status